EHC Q2 Deep Dive: Discharge Growth and Capacity Expansion Drive Upbeat Outlook

Health care services provider Encompass Health (NYSE:EHC) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 12% year on year to $1.46 billion. The company’s full-year revenue guidance of $5.93 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $1.40 per share was 15.8% above analysts’ consensus estimates.

Is now the time to buy EHC? Find out in our full research report (it’s free).

StockStory’s Take

Encompass Health’s second quarter was marked by broad-based discharge growth and operational improvements, resulting in a positive market reaction. Management attributed the quarter’s performance to increased patient volumes across geographies and payer types, with complex neurological and stroke cases standing out as key drivers. CEO Mark Tarr specifically noted, “Our dedicated and highly competent clinical teams continue to deliver outstanding patient outcomes,” highlighting the company’s focus on treating patients with significant medical needs. Additionally, strategic bed expansions and new facility openings contributed to the company’s ability to meet rising demand.

Looking ahead, Encompass Health’s updated guidance reflects expectations for continued capacity additions and robust demand for inpatient rehabilitation, particularly as the aging U.S. population drives higher utilization. Management cited plans to open several new hospitals and expand existing facilities, emphasizing that demographic trends support sustained growth. President and CEO Mark Tarr pointed to the growing Medicare beneficiary population, stating, “The demand for inpatient rehabilitation services remains considerably underserved, and continues to grow as the U.S. population ages.” The company’s focus remains on expanding access to care while maintaining quality outcomes and operational efficiency.

Key Insights from Management’s Remarks

Management credited strong discharge growth, quality outcomes, and targeted facility investments as primary factors in the quarter’s results, while also emphasizing continued improvements in labor management and payer mix.

• Discharge growth across specialties: Management highlighted that total discharges increased 7.2%, with particularly strong performance in neurological and stroke cases. These complex, higher-acuity patients contributed to both revenue growth and Encompass Health’s market differentiation.
• Facility expansion and bed additions: The company opened a new 60-bed hospital and added beds to existing facilities during the quarter, with additional hospitals and expansions planned for the rest of the year. This expansion supports the ability to meet growing patient demand, especially in underserved markets.
• Labor and hiring improvements: Centralized talent acquisition and retention strategies led to net hiring gains and a return to pre-pandemic turnover rates. Management emphasized that focused career development for clinical staff, especially nurses, has helped reduce turnover and improve operational stability.
• Payer mix and managed care pricing: The company saw favorable trends in its payer mix, driven by growth in the Veterans Affairs (VA) Community Care Network, which now accounts for nearly 18% of managed care business and provides pricing at Medicare rates. This shift supported stronger managed care pricing overall.
• Quality and data-driven outcomes: Encompass Health continued to outperform industry averages on patient outcomes, including discharge community rates and patient satisfaction. The company’s ongoing investment in clinical protocols and data-driven quality measurement was cited as a key differentiator for referral partners and joint venture stakeholders.

Drivers of Future Performance

Management’s outlook for the remainder of 2025 centers on expanding facility capacity, favorable demographic trends, and continued focus on clinical quality, while monitoring cost pressures and regulatory changes.

• Capacity additions and new markets: The company plans to open multiple new hospitals and add beds to existing sites, targeting both current and new geographies. Management views these expansions as essential to capturing demand from the rapidly growing senior population.
• Labor efficiency and retention focus: Continued investment in recruitment, workforce optimization, and retention initiatives is expected to support stable operations. Management remains attentive to potential cost pressures from salaries and benefits, but expects moderation in expense growth as hiring and turnover stabilize.
• Payer and regulatory landscape: Shifts in payer mix, particularly growth in managed care contracts like the VA, are expected to support revenue per discharge. Management also highlighted ongoing monitoring of regulatory changes, such as potential updates to Medicare reimbursement and quality measurement requirements, as potential sources of both opportunity and risk.

Catalysts in Upcoming Quarters

In the upcoming quarters, the StockStory team will monitor (1) the pace and impact of new hospital openings and bed expansions, (2) sustained discharge growth across high-acuity specialties like neurology and stroke, and (3) further improvements in labor retention and efficiency. Additionally, we will track regulatory developments affecting reimbursement rates and quality metrics, as well as shifts in payer mix, particularly the expansion of managed care and VA contracts.

Encompass Health currently trades at $118.63, up from $109.21 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Stocks That Trumped Tariffs

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.